AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies.
dc.contributor.author | Omlin, A | |
dc.contributor.author | Jones, R | |
dc.contributor.author | van der Noll, R | |
dc.contributor.author | Satoh, T | |
dc.contributor.author | Niwakawa, M | |
dc.contributor.author | Smith, S A | |
dc.contributor.author | Graham, J | |
dc.contributor.author | Ong, M | |
dc.contributor.author | Finkelman, R | |
dc.contributor.author | Schellens, J | |
dc.contributor.author | Zivi, A | |
dc.contributor.author | Crespo, M | |
dc.contributor.author | Riisnaes, R | |
dc.contributor.author | Nava Rodrigues, D | |
dc.contributor.author | Malone, Malcolm D | |
dc.contributor.author | Dive, Caroline | |
dc.contributor.author | Sloane, Robert | |
dc.contributor.author | Moore, David | |
dc.contributor.author | Alumkal, J | |
dc.contributor.author | Dymond, A | |
dc.contributor.author | Dickinson, P | |
dc.contributor.author | Ranson, M | |
dc.contributor.author | Clack, G | |
dc.contributor.author | de Bono, J | |
dc.contributor.author | Elliott, Tony | |
dc.date.accessioned | 2015-07-21T10:30:49Z | en |
dc.date.available | 2015-07-21T10:30:49Z | en |
dc.date.issued | 2015-06 | en |
dc.identifier.citation | AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies. 2015, 33 (3):679-90 Invest New Drugs | en |
dc.identifier.issn | 1573-0646 | en |
dc.identifier.pmid | 25920479 | en |
dc.identifier.doi | 10.1007/s10637-015-0235-5 | en |
dc.identifier.uri | http://hdl.handle.net/10541/560760 | en |
dc.description.abstract | AZD3514 is a first-in-class, orally bio-available, androgen-dependent and -independent androgen receptor inhibitor and selective androgen-receptor down-regulator (SARD). | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Investigational new drugs | en |
dc.title | AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies. | en |
dc.type | Article | en |
dc.contributor.department | Prostate Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK | en |
dc.identifier.journal | Investigational New Drugs | en |
html.description.abstract | AZD3514 is a first-in-class, orally bio-available, androgen-dependent and -independent androgen receptor inhibitor and selective androgen-receptor down-regulator (SARD). |